london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Intravitreal anti-VEGF for idiopathic juxtafoveal telangiectasia treatment

Poster Details

First Author: W.Prasartritha THAILAND

Co Author(s):    S. Sukavatcharin   B. Tipsuriyaporn               0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To evaluate the effect of intravitreal anti-VEGF for non-proliferative idiopathic juxtafoveal telangiectasia (IJT) in Thailand.

Setting:

At Ophthalmology Department, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Methods:

Retrospective, non-comparative case series of 10 eyes (10 patients; 9 male and 1 female) with IJT that were treated with monthly injection of intravitreal anti-VEGF(Ranibizumab or Bevacizumab) between July 2012 to March 2014 at Ramathibodi Hospital, Thailand. All patients were received complete ophthalmic examination, including best-corrected visual acuity (BCVA), fundus photograph, optical coherence tomography and fluorescein angiogram. Data were collected and interpreted by retinal specialist in every follow up period (1st, 3rd visit and the last follow up).

Results:

Mean age was 52.9 years. Mean follow up time was 12±4 months. Mean BCVA increased from LogMAR 0.38 ±0.12 at baseline to 0.26±0.24, 0.15±0.14 and 0.17±0.14 at 1st, 3rd month and the last follow up period, respectively. Mean intravitreal injection was 3.25 times with one-month interval. Mean central retinal thickness was 363.4 ± 120 µm at baseline and decreased to 297.0±100 µm, 250.1 ± 50 µm and 236.1 ± 45 µm at 1st, 3rd month and the last follow up period, respectively. FA showed the reduction of leakage and staining area after the end of treatment. No systemic and ocular adverse event was found in this study.

Conclusions:

Intravitreal Anti-VEGF injection might be the promising treatment for IJT, in term of improvement of BCVA, decrease central retinal thickness and FA leakage.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy